Alkermes Investigational Site
Overland Park, Kansas, 66212, United States
NCT Number: NCT02479308
This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 1
Overland Park, Kansas, 66212, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single administration
Daily administration for a total of 12 dosing days
Placebo will be matched to Moxifloxacin or ALKS 5461
Time frame: Up to 14 days
Time frame: Up to 14 days
Time frame: Up to 13 days
Time frame: Up to 14 days
Findings not present at baseline
Time frame: Up to 14 days
Time frame: Up to 14 days
Time frame: Up to 14 weeks
Time frame: Up to 14 days
Time frame: Up to 14 days
Time frame: Up to 14 days
Time frame: Up to 14 days
Time frame: Up to 14 days
Time frame: Up to 14 days
Alkermes, Inc.
Industry
The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details